Literature DB >> 14734787

Blunted coronary flow reserve in systemic sclerosis.

A Sulli1, M Ghio, G P Bezante, L Deferrari, C Craviotto, V Sebastiani, M Setti, A Barsotti, M Cutolo, F Indiveri.   

Abstract

OBJECTIVES: We investigated whether the non-invasive determination of coronary flow reserve (CFR), as evaluated by transthoracic Doppler echocardiography, might be a potential method to detect early dysfunction of cardiovascular system in patients affected by systemic sclerosis (SSc) without clinical signs or symptoms of cardiac impairment. The possible correlations between the CFR values and the duration of the disease, specific autoantibodies and cutaneous involvement subsets were investigated.
METHODS: Forty-four consecutive patients affected by SSc were analysed. The CFR was detected in the distal left anterior descending coronary artery by contrast-enhanced transthoracic second harmonic Doppler in all SSc patients and in 16 healthy controls. CFR was assessed at rest and during hyperaemia induced by administration of adenosine at 0.14 mg/kg/min over 5 min. The CFR was calculated as the ratio between hyperaemic (peak adenosine infusion) and resting peak diastolic velocity (PdvCFR) and resting velocity time integral (VtiCFR). Past medical history was carefully investigated.
RESULTS: Both PdvCFR and VtiCFR were significantly reduced in SSc patients when compared with controls (P<0.0001). In particular, both PdvCFR and VtiCFR were significantly lower in patients with dSSc when compared with patients affected by lSSc (P<0.02 and P<0.04 respectively). No statistically significant correlation was found between CFR values and history of smoking, serum levels of cholesterol or triglycerides, blood pressure, age of patients, duration of SSc and serum autoantibody positivity for ANA, ACA and Scl70.
CONCLUSIONS: CFR is often reduced in SSc patients. CFR was lower in patients with dSSc than in those affected by lSSc. A reduced CFR value should be considered an indirect sign of heart involvement in scleroderma, but its clinical and prognostic implications need to be clarified.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734787     DOI: 10.1093/rheumatology/keh087

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

Review 1.  The right ventricle in scleroderma (2013 Grover Conference Series).

Authors:  Paul M Hassoun
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

2.  Heart involvement in systemic sclerosis: a combined echocardiographic and scintigraphic study.

Authors:  Charalampos Papagoras; Kerstin Achenbach; Niki Tsifetaki; Spyridon Tsiouris; Andreas Fotopoulos; Alexandros A Drosos
Journal:  Clin Rheumatol       Date:  2014-05-22       Impact factor: 2.980

3.  Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study.

Authors:  Antonello D'Andrea; Michele D'Alto; Marco Di Maio; Serena Vettori; Nicola Benjamin; Rosangela Cocchia; Paola Argiento; Emanuele Romeo; Giovanni Di Marco; Maria Giovanna Russo; Gabriele Valentini; Raffaele Calabrò; Eduardo Bossone; Ekkehard Grünig
Journal:  Clin Rheumatol       Date:  2016-04-27       Impact factor: 2.980

4.  Myocardial perfusion defects in scleroderma detected by contrast-enhanced cardiovascular magnetic resonance.

Authors:  Nicolò Schicchi; Gianluca Valeri; Gianluca Moroncini; Giacomo Agliata; Luca Salvolini; Armando Gabrielli; Andrea Giovagnoni
Journal:  Radiol Med       Date:  2014-06-07       Impact factor: 3.469

5.  Coronary flow reserve in systemic rheumatic diseases: a systematic review and meta-analysis.

Authors:  Gian Luca Erre; Giorgio Buscetta; Panagiotis Paliogiannis; Arduino Aleksander Mangoni; Ciriaco Carru; Giuseppe Passiu; Angelo Zinellu
Journal:  Rheumatol Int       Date:  2018-05-07       Impact factor: 2.631

Review 6.  The burden and measurement of cardiovascular disease in SSc.

Authors:  Mo Yin Mok; Chak Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2010-06-01       Impact factor: 20.543

Review 7.  Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings.

Authors:  Hasya Zinger; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

8.  One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients.

Authors:  Mara Boschetti; Sergio Agosti; Valeria Albanese; Laura Casalino; Claudia Teti; Gian Paolo Bezante; Claudio Brunelli; Manuela Albertelli; Diego Ferone
Journal:  Endocrine       Date:  2016-04-13       Impact factor: 3.633

9.  Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure.

Authors:  Paola Ximena Coral-Alvarado; Maria Fernanda Garces; Jorge Eduardo Caminos; Antonio Iglesias-Gamarra; José Félix Restrepo; Gerardo Quintana
Journal:  Int J Rheumatol       Date:  2010-08-24

10.  Prognostic impact of coronary microcirculation abnormalities in systemic sclerosis: a prospective study to evaluate the role of non-invasive tests.

Authors:  Alessandra Vacca; Roberta Montisci; Pietro Garau; Paolo Siotto; Matteo Piga; Alberto Cauli; Massimo Ruscazio; Luigi Meloni; Sabino Iliceto; Alessandro Mathieu
Journal:  Arthritis Res Ther       Date:  2013-01-09       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.